United Therapeutics (UTHR) Equity Average (2016 - 2025)
Historic Equity Average for United Therapeutics (UTHR) over the last 16 years, with Q3 2025 value amounting to $6.9 billion.
- United Therapeutics' Equity Average rose 1666.12% to $6.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 billion, marking a year-over-year increase of 1666.12%. This contributed to the annual value of $6.2 billion for FY2024, which is 1527.9% up from last year.
- As of Q3 2025, United Therapeutics' Equity Average stood at $6.9 billion, which was up 1666.12% from $7.0 billion recorded in Q2 2025.
- United Therapeutics' Equity Average's 5-year high stood at $7.0 billion during Q2 2025, with a 5-year trough of $3.4 billion in Q1 2021.
- For the 5-year period, United Therapeutics' Equity Average averaged around $5.1 billion, with its median value being $5.3 billion (2023).
- As far as peak fluctuations go, United Therapeutics' Equity Average soared by 475.69% in 2024, and later soared by 2669.16% in 2025.
- United Therapeutics' Equity Average (Quarter) stood at $3.9 billion in 2021, then rose by 20.16% to $4.7 billion in 2022, then increased by 24.98% to $5.8 billion in 2023, then rose by 7.25% to $6.3 billion in 2024, then grew by 9.72% to $6.9 billion in 2025.
- Its Equity Average stands at $6.9 billion for Q3 2025, versus $7.0 billion for Q2 2025 and $6.6 billion for Q1 2025.